12 dia park
TRANSCRIPT
DiaPark Test System for Early Diagnostics of
Parkinson’s Disease
DiaPark
Razina Nigmatullinadeputy CEO,LLC “Centre for the early diagnostics of the neurodegenerative diseases”Kazan, Russian [email protected]+7 (927) 429 04 66
DiaPark Test System For Early Diagnostics Of Parkinson’s Disease 2
0
20
6080
40
100%
0
20
6080
40
100
10 20 807060504030
%, Neurons
Neuronal cell deathTHE FIRST SYMPTOMS
ONSET OF THE DISEASE
Compensatory mechanisms
Development objectives:
Early diagnostics; Preventive treatment.
Limb tremor (tremor). Violation and stiffness of gait and speech
Trends:1. Shift towards younger patients, 15% of the patients are <40 years;2. The aging of the population. World population older than 60 years: in 2010 10%, 2040 25% of the population.
Caring for the growing number of patients is very expensive
Age
PARKINSON'S DISEASE IS INSIDIOUS: WHEN SYMPTOMS START APPEARING, IT IS IMPOSSIBLE TO CURE
DiaPark Test System For Early Diagnostics Of Parkinson’s Disease 3
DiaPark – COST-EFFECTIVE EARLY WARNING SYSTEM
Test Kit:1. Immunological chips;2. Genetic chips;3. Electrophysiological tests
(EEG, ECG, EMG + program).
Cost-effective, mass, preventive care; Only selective diagnostics on expensive PET scan; Treatment of earlier stage disease effectively and cheaply.
Newly developed technology allows detection of Parkinson's disease for several years before the appearance of specific symptoms
DiaPark Test System For Early Diagnostics Of Parkinson’s Disease 4
METHOD DiaPark IS ECONOMICALLY FEASIBLE FOR MASS DIAGNOSTICS
Radiation safetyThe survey of large population groups
Accuracy Price
DiaPark 85- 90% $150
PET 98-100% $6000
DiaPark$150 / patient
PET$6000 / patient
1 millionDiaPark
25 thousand PET
Improving the lives of millions and savings billions in money
??
DiaPark Test System For Early Diagnostics Of Parkinson’s Disease 5
THE TEAM OF PROFESSIONALS
Ugrumov M.V. – CEO, CSO. International experience in
Neuroscience. More than 25 years of work in France, Japan, Germany and USA;
Author of 250 articles in leading international journals.
Nigmatullina R.R. - COO. International experience; Improving competencies
of technology commercialization «Fast trac Planning»;
Ph.D., professor.
Under the guidance of Academician M.V.Ugrumov team working from 2005 on the project "Neurodegenerative diseases: development of preclinical diagnostics and preventive treatment "
Georgieva S.G. PhD., Slominsky P.A., PhD. - Examination of gene expression;Kudrin V.S. PhD., Pronina T.S. PhD.- Determination of monoamines and hormones;Obukhov Y.V., PhD. - Electrophysiology, mathematical processing, informatics technologies;
DiaPark Test System For Early Diagnostics Of Parkinson’s Disease 6
YOU HAVE A CHANCE FOR INVESTING $2 MILLION IN DiaPark
1. The project is at the stage prototype development. Attracted $800 thousand of R&D funding through Federal Target Programs and grants; Grants and investments raised so far $200 thousand;
2. $2 million will be spent on: Clinical trials in Russia, Europe and the USA International patenting Product certification and registration Marketing Promotion of products on the world market
3. Output:Attracting investors for the next stage in the global market;Sale to a strategic investor (Amarantus BioSciences, Rainbow BioSciences, etc.).
DiaPark Test System For Early Diagnostics Of Parkinson’s Disease 7
EARLY DIAGNOSTICS OF PARKINSON'S DISEASE MAY SAVE YOUR LIFE!
DiaPark:1. Saves human lives2. Saves money in healthcare 3. Offers You a great investment opportunity
Razina Nigmatullinadeputy CEO,
LLC “Centre for the early diagnostics of the neurodegenerative diseases”
Kazan, Russian [email protected]
+7 (927) 429 04 66